Date: 2013-11-20
Type of information: R&D agreement
Compound: discovery services
Company: Biofocus, a Galapagos Company (UK - Belgium) Boehringer Ingelheim (Germany)
Therapeutic area: undisclosed
Type agreement: R&D
collaboration
Action mechanism:
Disease: undisclosed
Details: * On November 20, 2013, Galapagos has announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim. Under the terms of the agreement, BioFocus will apply its extensive drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Financial terms:
Latest news:
